Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury
NCT03007537 · Nanjing First Hospital, Nanjing Medical University · NA · terminated · last registry update 2023-01-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of funds” | – | Registry record, Nanjing First Hospital, Nanjing Medical University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EPOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-29Also stopped (terminated): Children's Hospital of Fudan University, Epo + Normal saline (NCT02550054)
- 2023-11-18Phase 3 first posted: Ain Shams University, erythropoietin + Triamcinolone acetonide (NCT06135259)
- 2023-08-24Results posted on the registry: Celgene, Luspatercept (NCT03194542)
- 2023-07-25Results posted on the registry: GlaxoSmithKline, Daprodustat + rhEPO (NCT03457701)
- 2023-07-25Results posted on the registry: University of New Mexico, Darbepoetin Alfa + Normal Saline (NCT03071861)
- 2023-07-18Phase 3 first posted: Bristol-Myers Squibb, Luspatercept + Epoetin Alfa (NCT05949684)
- 2023-06-18Phase 3 first posted: The First Affiliated Hospital of Soochow University, Decitabine + Granulocyte Colony-Stimulating Factor (NCT05907499)
- 2023-03-15Phase 3 first posted: Hallym University Medical Center, Ferric Derisomaltose Injection + Darbepoetin Alfa Injection (NCT05768997)
- 2023-02-28Phase 3 first posted: Asociación para Evitar la Ceguera en México, Recombinant human erythropoietin 4,000 UI and 2,000 UI + Methylprednisolone succinate 500 mg (NCT05748561)
- 2023-01-30Results posted on the registry: University of California, San Francisco, Normal saline placebo + Erythropoietin (NCT02811263)
- 2023-01-30Phase 3 first posted: Blau Farmaceutica S.A., Erythropoietin (NCT05704894)
- 2023-01-26Also stopped (withdrawn): Karyopharm Therapeutics Inc, Selinexor (NCT02431351)
- 2022-12-30Phase 3 first posted: The First Affiliated Hospital of Soochow University, decitabine + umbilical cord blood (NCT05669079)
- 2022-11-30Also stopped (terminated): Amgen, Darbepoetin alfa + Placebo (NCT00858364)
- 2022-11-29Also stopped (terminated): Amgen, Darbepoetin Alfa + Placebo (NCT00436748)
- 2022-09-29Results posted on the registry: Akebia Therapeutics, Vadadustat + Epoetin Alfa (NCT03799627)
- 2022-09-13Results posted on the registry: Kyntra Bio, Roxadustat (NCT04410198)
- 2022-07-27Phase 3 first posted: Shahid Beheshti University of Medical Sciences, Prescription of placebo + Erythropoietin prescription (NCT05476042)
- 2022-07-26Results posted on the registry: Kyntra Bio, Roxadustat (NCT04484857)
- 2022-07-18Results posted on the registry: Akebia Therapeutics, Vadadustat + Darbepoetin alfa (NCT02865850)
- 2022-07-01Results posted on the registry: Akebia Therapeutics, AKB-6548 + Placebo (NCT01906489)
- 2022-07-01Results posted on the registry: Akebia Therapeutics, AKB-6548 + Placebo (NCT01381094)
- 2022-07-01Results posted on the registry: Akebia Therapeutics, AKB-6548 + AKB-6548 (NCT02260193)
- 2022-07-01Results posted on the registry: Akebia Therapeutics, AKB-6548 (NCT01235936)
- 2022-06-28Results posted on the registry: Akebia Therapeutics, Vadadustat + Darbepoetin alfa (NCT02892149)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision